English | Neola Medical

Neola Medical Completes Enrollment in Swedish Clinical Pilot Study

Mar 16, 2026

Neola Medical announces completion of patient enrollment in its clinical pilot study on preterm born babies in Sweden. All ten babies have now been included in the study, marking an important milestone with the first real-world use of Neola® in its target patient...

Redeye Interview: Neola Medical Q4 2025 with CEO Hanna Sjöström

Feb 12, 2026

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the key milestones from Neola Medical’s Q4 2025 report.Watch the full interview here: Redeye Interview Neola Medical Q4 2025 with CEO Hanna Sjöström Access...

Neola Medical’s Q4 report presentation hosted by Investor Studios

Feb 12, 2026

Catch up on the highlights from Neola Medical’s year-end Q4 report for 2025. CEO Hanna Sjöström reflects on a year marked by key milestones as we entered the clinical phase, strengthened the organization, and continued to build on our most...

Neola Medical Q4 Report 2025 – Advancing IP Protection as a Core Strategic Asset across Key Markets

Feb 12, 2026

During the quarter four new patents were granted, adding in total of seven new patent grants during 2025. This marks Neola Medical’s strongest year to date in terms of IP protection across all key target markets – Europe, the U.S. and China. In addition,...

Medtech Leaders and Clinical Expert Call for MDR Reform in Dagens Industri

Feb 6, 2026

In a debate article published in Dagens Industri, four medtech CEOs, including Neola Medical’s CEO Hanna Sjöström, together with a professor at Lund University and senior clinician at Skåne University Hospital, highlight how the EU MDR framework...

« Older Entries